Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead's twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, building the case for regulatory approval of the treatment.

Gilead's HIV-prevention drug cut infections by 96%, boosting stock

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The data sets the stage for likely FDA approval of Lenacapavir for HIV prevention.

Gilead's twice-yearly shot cut HIV infections by 96% in trial

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV). There were 2 incident cases among 2,180 participants, corresponding to 99.9% of participants not acquiring HIV infection in the lenacapavir g.

Gilead's Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial

Gilead Sciences, Inc. (NASDAQ:GILD ) Baird Global Healthcare Conference September 10, 2024 10:50 PM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney [Starts abruptly] biotech analysts here. [Technical Difficulty] to have presenting with us next, Gilead Sciences.

Gilead Sciences, Inc. (GILD) Baird Global Healthcare Conference (Transcript)

FOSTER CITY, Calif. & BURLINGAME, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. This collaboration will deploy Genesis' field-leading AI platform, GE.

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

CNH Industrial NV

EPR Properties

General Electric

The 'Undercovered' Dozen series highlights 12 lesser-known stocks, offering fresh investment ideas and encouraging community discussion on their potential. Gen Alpha argues that EPR Properties, a diversified experiential REIT, shows promising tenant rent coverage and stability, especially with AMC's debt refinancing. Gilead Sciences' strong Q2 2024 results, robust HIV franchise, and high dividend yield support a continued "Buy" from ALLKA Research.

Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial +

Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo 2024 Healthcare Conference September 4, 2024 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Good morning, my name is Mohit Bansal. I'm one of the biopharma analyst here at Wells Fargo.

Gilead Sciences, Inc. (GILD) Wells Fargo 2024 Healthcare Conference (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley.

Gilead Sciences, Inc. (GILD) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company's broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif. Data to be highlighted across three oral presentations include: initial results from two cohorts of the EVOKE-02 study of Trodelvy® (sacituzumab govitecan-hziy).

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

Merck

Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.

Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street

SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics to evaluate AVZO-021, a potential best-in-class CDK2 inhibitor, in combination with Trodelvy®, Gilead's Trop-2 directed ADC.

Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer

Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Oncology will especially contribute to growth in the years to come, and maybe Gilead Sciences will also be a player in the anti-obesity market. The stock is still trading for a reasonable valuation multiple and in case of a potential recession, pharmaceutical companies are often a good, recession-resilient pick.

Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the company's HIV franchise amounted to about $4.75 billion in the second quarter, an increase of 9.3% quarter-on-quarter. In addition, on August 14, 2024, the FDA approved Livdelzi in combination with UDCA for the treatment of primary biliary cholangitis.

Gilead Sciences: Buy This Bargain Before It's Gone

Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset. Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset.

Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi

Bristol-Myers

Vertex Pharmaceuticals

Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.

Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday

While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.

Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 4 at 11:00 AM Eastern Time Morgan Stanley Annual Global Healthcare Conference on Thursday, September 5 at 12:20 PM Eastern Time Baird Global Healthcare Conference on Tuesday, September 10 at 10:50 AM Eastern Time The live webcasts can be accessed at the company's investors.

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.

Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi

Gilead Sciences says counterfeit versions of its HIV medications were being sold out of two New York pharmacies. Court documents alleged a twice-convicted medical fraudster wearing a court-ordered GPS ankle monitor was behind the scheme.

Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. The use of Livdelzi is not recommended for people who have or develop decompensated ci.

Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Colgate-Palmolive

Campbell Soup

Con Ed

Medtronic

Philip Morris

Walmart

Although the market may have hit a calm relative to the wild volatility witnessed earlier this month, we may not be out of the woods yet. Sure, the CBOE Volatility Index or the VIX has come down significantly from its earlier highs.

7 Defensive Stocks to Buy as Investors Seek Shelter

The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' drug for a chronic and potentially fatal liver disease that mostly affects women.

US FDA approves Gilead's liver disease drug

AbbVie

AbbVie offers reliable income and solid growth prospects. Bristol Myers Squibb is a stable dividend stock to buy and hold.

3 Stocks Retirees Should Absolutely Love

On Thursday, Gilead Sciences, Inc. GILD reported second-quarter revenue of $6.95 billion, beating the consensus of $6.72 billion.

News for Gilead Sciences Stock (GILD)